Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8905 results

  1. Guidance on the use of metal on metal hip resurfacing arthroplasty (TA44)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Withdrawn guidance

  2. Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

    This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

    Withdrawn guidance

  3. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.

    Withdrawn guidance

  4. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

    This guidance has been updated and replaced by NICE technology appraisal guidance 531.

    Withdrawn guidance

  5. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Withdrawn guidance

  6. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  7. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  8. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  9. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  10. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  11. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  12. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  13. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  14. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)

    This guidance has been updated and replaced by NICE technology appraisal guidance 427.

    Withdrawn guidance

  15. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance